Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07282613 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Not yet
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT07282613: Clinical Trial Phase 3 study, sponsored by Novo Nordisk A/S.
NCT07282613 is a Phase 3 study that has not yet begun recruiting, run by Novo Nordisk A/S. The registered enrollment target is 80 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07282613, a Phase 3 study, has not yet begun recruiting, sponsored by Novo Nordisk A/S.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The study will last for about 1 year and 3 months.
Primary Outcome
Measured as percentage (%) of HbA1c.
Interventions
- DRUG CagriSema (Cagrilintide B and Semaglutide I)
- DRUG Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-08-04 |
| Est. Completion | 2030-03-30 |
| Phase | Phase 3 |
What is known before NCT07282613 opens enrollment
NCT07282613 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which CagriSema (Cagrilintide B and Semaglutide I) is the first listed.
NCT07282613 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07282613 about?
NCT07282613 is a clinical study titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes". The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part...
What is the current status of trial NCT07282613?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2026-08-04. Estimated completion is 2030-03-30.
What interventions are being tested in trial NCT07282613?
The interventions under investigation include: CagriSema (Cagrilintide B and Semaglutide I) (DRUG), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) (DRUG).
Who is sponsoring clinical trial NCT07282613?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07282613's enrollment target sits among peer trials
80 1755th of 2000 higher than 233 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI